EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes
H Xu, G Yang, W Li, J Li, X Hao, P Xing, Y Yang… - Frontiers in …, 2021 - frontiersin.org
Background Approximately 3–5% of patients with epidermal growth factor receptor (EGFR)
mutation-positive non-small cell lung cancer (NSCLC) harbor exon 18 mutations. The …
mutation-positive non-small cell lung cancer (NSCLC) harbor exon 18 mutations. The …
Effectiveness of EGFR tyrosine kinase inhibitors in advanced non‐small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study
M Kanazu, M Mori, M Kimura, K Nishino… - Thoracic …, 2021 - Wiley Online Library
Background Epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) therapy
is the standard treatment for advanced non‐small cell lung cancer (NSCLC) harboring …
is the standard treatment for advanced non‐small cell lung cancer (NSCLC) harboring …
[HTML][HTML] Efficacy of targeted therapy in patients with non-small cell lung cancer harboring very rare mutations in EGFR exon 18
Y Zhang, H Zeng, C Qi, S Tan, Q Huang… - Translational Lung …, 2024 - ncbi.nlm.nih.gov
Background Somatic mutations in epidermal growth factor receptor (EGFR) exon 18 are
classified as uncommon or rare mutations in non-small cell lung cancer (NSCLC), in this …
classified as uncommon or rare mutations in non-small cell lung cancer (NSCLC), in this …
Efficacy of EGFR-Tyrosine Kinase Inhibitors for advanced non-small cell lung cancer patients harboring rare EGFR mutations of exon 18 E709X
Y Hao, M Xu, H Zhou, J Si, Y Fang, C Xu, Z Song - Medical Oncology, 2022 - Springer
EGFR-tyrosine kinase inhibitors (TKIs) show efficacy against lung cancer, and afatinib has
been used as a standard therapy for patients with non-small cell lung cancer (NSCLC) with …
been used as a standard therapy for patients with non-small cell lung cancer (NSCLC) with …
EGFR exon 18 mutations in lung cancer: molecular predictors of augmented sensitivity to afatinib or neratinib as compared with first-or third-generation TKIs
Y Kobayashi, Y Togashi, Y Yatabe, H Mizuuchi… - Clinical cancer …, 2015 - AACR
Purpose: Lung cancers harboring common EGFR mutations respond to EGFR tyrosine
kinase inhibitors (TKI), whereas exon 20 insertions (Ins20) are resistant to them. However …
kinase inhibitors (TKI), whereas exon 20 insertions (Ins20) are resistant to them. However …
Clinical outcomes of advanced NSCLC patients with different EGFR exon 19 deletion subtypes treated with first‐line tyrosine kinase inhibitors: A single‐center …
Y Gu, J Yu, H Hu, H Zhang, B Cao, L Liang - Thoracic Cancer, 2023 - Wiley Online Library
Background Clinical significance of various subtypes of epidermal growth factor receptor
(EGFR) exon 19 deletion (ex19del) mutation in non‐small cell lung cancer (NSCLC) …
(EGFR) exon 19 deletion (ex19del) mutation in non‐small cell lung cancer (NSCLC) …
Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced …
Y Zhang, J Sheng, S Kang, W Fang, Y Yan, Z Hu… - PloS one, 2014 - journals.plos.org
Backgrounds It has been extensively proved that the efficacy of epidermal growth factor
receptor-tyrosine kinase inhibitors (EGFR-TKIs) is superior to that of cytotoxic chemotherapy …
receptor-tyrosine kinase inhibitors (EGFR-TKIs) is superior to that of cytotoxic chemotherapy …
[HTML][HTML] Association between EGFR exon 19 or exon 21 mutations and survival rates after first‑line EGFR‑TKI treatment in patients with non‑small cell lung cancer
H Jiang, M Zhu, Y Li, Q Li - Molecular and clinical …, 2019 - spandidos-publications.com
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‑TKI) is the first‑line
treatment for patients with advanced non‑small‑cell lung cancer (NSCLC) who have an …
treatment for patients with advanced non‑small‑cell lung cancer (NSCLC) who have an …
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study
Objectives To compare the survival of first-and second-generation tyrosine kinase inhibitors
(TKIs) in patients with rare EGFR exon 18 and exon 20 mutation-positive non-small cell lung …
(TKIs) in patients with rare EGFR exon 18 and exon 20 mutation-positive non-small cell lung …
EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: molecular heterogeneity and treatment outcome from nationwide real …
G Yang, J Li, H Xu, Y Yang, L Yang, F Xu, B Xia… - Lung Cancer, 2020 - Elsevier
Objectives To describe the treatment patterns and outcomes of Chinese non-small cell lung
cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) exon 20 insertion …
cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) exon 20 insertion …
相关搜索
- egfr exon clinical outcomes
- egfr exon lung cancer
- egfr exon treatment patterns
- clinical outcomes treatment patterns
- egfr exon insertion mutation
- egfr exon real life
- egfr exon survival rates
- egfr mutations tyrosine kinase
- egfr exon nsclc patients
- clinical outcomes nsclc patients
- egfr exon afatinib or neratinib
- egfr exon deletion subtypes
- egfr exon targeted therapy
- patient outcomes insertion mutation
- clinical outcomes deletion subtypes
- afatinib or neratinib lung cancer